CD274 and cancer: Immunotherapy has rapidly evolved into a standard treatment for multiple cancer types, including TNBC.CPIs, such as the anti-PD-L1 antibody atezolizumab and the anti-PD-1 antibody pembrolizumab, have been approved for use in combination with chemotherapy as first-line therapy for PD-L1-positive (PD-L1 +) advanced TNBC.